Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Core Viewpoint - The average brokerage recommendation (ABR) for Boston Scientific (BSX) is 1.25, indicating a strong buy sentiment from analysts, but reliance solely on this metric may not be advisable due to potential biases in brokerage recommendations [1][2]. Brokerage Recommendation Trends for BSX - Boston Scientific has an ABR of 1.25, with 23 out of 28 recommendations classified as Strong Buy, accounting for 82.1% of total recommendations, while 10.7% are classified as Buy [1]. - Studies suggest that brokerage recommendations often lack success in guiding investors towards stocks with significant price appreciation potential [2]. - Brokerage firms tend to exhibit a positive bias in their ratings, with a ratio of five Strong Buy recommendations for every Strong Sell [2][3]. Zacks Rank vs. ABR - Zacks Rank is a proprietary stock rating tool that categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell) based on earnings estimate revisions, which are more reliable indicators of near-term stock price performance compared to ABR [3][4]. - The ABR is based solely on brokerage recommendations and may not be up-to-date, while Zacks Rank reflects timely earnings estimate revisions [5][6]. Investment Potential for BSX - The Zacks Consensus Estimate for Boston Scientific's earnings has increased by 0.1% to $2.40 over the past month, indicating growing analyst optimism [7]. - The Zacks Rank for Boston Scientific is 2 (Buy), suggesting that the stock may have potential for price appreciation in the near term [7].

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 5.2% over the past month. The stock hit a new 52-week high of $84.89 in the previous session. Boston Scientific has gained 44.8% since the start of the year compared to the 11.6% move for the Zacks Medical sector and the 15.8% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't misse ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] Zacks Style Scores - Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, and Price/Sales [2] - The Growth Score focuses on a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow [3] - The Momentum Score helps investors capitalize on price trends by evaluating short-term price changes and earnings estimate shifts [3] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for stock selection based on value, growth, and momentum [4] Zacks Rank and Style Scores Integration - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [5] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [6] - Stocks with lower ranks, even with high Style Scores, may still face downward earnings forecasts, increasing the risk of price declines [6] Company Spotlight: Boston Scientific - Boston Scientific Corporation, founded in 1979 and headquartered in Natick, MA, specializes in manufacturing medical devices for various interventional specialties globally [7] - The company holds a Zacks Rank of 2 (Buy) and a VGM Score of B, making it a strong candidate for growth investors [7] - Boston Scientific is projected to achieve year-over-year earnings growth of 17.1% for the current fiscal year, with 12 analysts raising earnings estimates for fiscal 2024 [7] - The Zacks Consensus Estimate for Boston Scientific has increased by $0.08 to $2.40 per share, with an average earnings surprise of 7.2% [7]

Boston Scientific Corporation (BSX) recently received the Food and Drug Administration’s (FDA) approval to expand the indication for current-generation INGEVITY+ Pacing Leads. Expanded indication for INGEVITY+ Pacing Leads means thin wires will be placed inside the heart that will be connected to an implantable device. It can be used to include conduction system pacing (CSP) and sensing of the left bundle branch area (LBBA) when connected to a single or dual-chamber pacemaker.The latest FDA approval enhance ...

Boston Scientific (BSX) closed the most recent trading day at $82.52, moving -1.19% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.03%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy index, added 0.2%.The the stock of medical device manufacturer has risen by 6.14% in the past month, leading the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%.Analysts and investors alike will be keeping a close eye on the performance of Boston ...

Core Viewpoint - Boston Scientific is experiencing significant investor interest as its shares reach all-time highs, driven by a strong portfolio of medical devices and favorable market conditions related to an aging population and chronic diseases [1]. Group 1: Company Overview - Boston Scientific is a global medical device manufacturer with a diverse range of products aimed at diagnosing and treating various medical conditions [1]. - The company has announced the acquisition of Silk Road Medical for $1.1 billion, which is expected to close by the end of the year [2]. - Boston Scientific operates primarily in two segments: MedSurg and Cardiovascular, with MedSurg generating 36% of total revenue and Cardiovascular generating 64% [3][4]. Group 2: Financial Performance - In Q2 2024, Boston Scientific reported EPS of 62 cents, exceeding analyst estimates, and revenues rose 14.5% year-over-year to $4.12 billion [5]. - The company expects net sales for Q3 2024 to grow 13% to 15% year-over-year, with adjusted EPS projected between 57 cents and 59 cents [7]. - For the full year 2024, Boston Scientific anticipates revenues to grow between $16.162 billion and $16.305 billion, surpassing consensus estimates [7]. Group 3: Segment Performance - The MedSurg segment reported 8% year-over-year organic growth in net sales to $1.483 billion, with an adjusted operating margin of 34.6% [3]. - The Cardiovascular segment achieved 19% year-over-year organic growth to $2.637 billion, with an adjusted operating margin of 28.9% [4]. Group 4: Growth Drivers - The Cardiovascular segment is expected to continue its growth, driven by the success of devices like POLARx and WATCHMAN FLX Pro, which received FDA approval in 2023 [6]. - The WATCHMAN device is particularly noted for its role in reducing stroke risk, while FARAPULSE devices are recognized as transformative in treating heart rhythm disorders [9]. Group 5: Market Position and Analyst Ratings - Boston Scientific's stock is currently rated as a "Moderate Buy" with a 12-month price target of $85.38, indicating a potential upside of 2.24% [7]. - The highest analyst price target for the stock is $95.00, reflecting positive sentiment among analysts [11].

Boston Scientific (BSX) closed at $82.94 in the latest trading session, marking a -0.14% move from the prior day. This change lagged the S&P 500's 1.07% gain on the day. At the same time, the Dow added 0.31%, and the tech-heavy Nasdaq gained 2.17%.The medical device manufacturer's stock has climbed by 9.4% in the past month, exceeding the Medical sector's gain of 3.34% and the S&P 500's gain of 2.92%.The upcoming earnings release of Boston Scientific will be of great interest to investors. The company is ex ...

UKRAINE - 2021/06/17: In this photo illustration, a Boston Scientific Corporation logo seen ... [+] displayed on a smartphone and pc screen in the background. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific (NYSE: BSX) has more than doubled in value since early January 2021 – jumping from levels of $36 then to around $82 now – vs. an increase of about 45% for the S&P 500 over this period. This can primarily be attribute ...

Boston Scientific Corporation (NYSE:BSX) - Key Takeaways from the 2024 Wells Fargo Healthcare Conference Company Overview - **Company**: Boston Scientific Corporation - **Event**: 2024 Wells Fargo Healthcare Conference - **Date**: September 4, 2024 Core Industry Insights - **Industry**: Medical Devices - **Market Growth**: The company is guiding for 13% to 14% organic growth in 2024, reflecting a significant turnaround from a decade ago when it was not growing [3][4] - **Category Leadership**: Boston Scientific has achieved category leadership in several areas, particularly in electrophysiology (EP) and WATCHMAN devices, with a strong growth profile [4][5] Financial Performance - **Organic Growth**: The company reported 14% organic growth in the first half of 2024, with expectations for similar growth in the second half [15][16] - **Operating Margin**: Operating margin performance was reported at 27.2% in Q2, with guidance for an expansion of 50 to 70 basis points in 2024 [18][19] Strategic Initiatives - **M&A Activity**: The company is continuing its tuck-in M&A strategy, with recent acquisitions of Axonics and Silk, while maintaining a strong balance sheet [6][7] - **Regulatory Environment**: Increased scrutiny from the FTC is acknowledged, but the company has always considered regulatory pathways in its M&A calculus [9] Product Development and Pipeline - **FARAPULSE Technology**: FARAPULSE is highlighted as a transformative technology in MedTech, with expectations for significant market penetration [10][28] - **EP Market Potential**: The EP market is expected to grow at over 20%, with WATCHMAN projected to expand from a $1.5 billion market today to $6 billion by 2030 [25][26] - **VC Portfolio**: The company has a robust venture capital portfolio that is expected to contribute to growth over the next 12 to 36 months [12] Geographic Expansion - **China and Japan**: The company has received approval in China and is on track for Japan, both markets estimated at $1 billion each [31][32] - **Market Dynamics**: The company anticipates that Japan may adopt FARAPULSE technology faster than China due to existing market conditions [32] Competitive Landscape - **Market Position**: Boston Scientific is currently the third-largest player in the EP market, with ambitions to become the second [41][42] - **Competitor Awareness**: The company is aware of its competitors, particularly J&J and Abbott, and is focused on enhancing its product portfolio to compete effectively [37][39] Future Outlook - **2025 Guidance**: The company plans to provide updated guidance during the fourth quarter earnings call, with expectations for continued strong performance in cardiology and interventional oncology [20][22] - **Long-term Goals**: The goal is to be the highest-performing MedTech company, with consistent growth and margin improvement [23][81] Additional Highlights - **WATCHMAN and OPTION Trial**: The upcoming OPTION trial results are anticipated to have significant implications for the WATCHMAN device and its market growth potential [49][53] - **AGENT Device**: The AGENT device is showing promise, with expectations for significant growth driven by reimbursement decisions [66][67] - **TAVR Business**: The ACURATE neo2 TAVR device is expected to file for US approval in the first half of 2025, with ongoing momentum in Europe [69][70] Conclusion Boston Scientific is positioned for strong growth in the medical device industry, driven by innovative products, strategic acquisitions, and a focus on operational efficiency. The company is optimistic about its future prospects, particularly in the electrophysiology and cardiology markets, while navigating a complex regulatory environment.